AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer Webcast (2021)
CME Available: [ Ссылка ]
At the conclusion of this course, participants will be able to:
1. Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC
2. Describe sequencing and indications for active treatment with approved agents in the management of nmCRPC
3. Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines
4. Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice
5. Analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer
ACKNOWLEDGEMENTS
Independent educational grant support provided by:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Exact Sciences Corporation
Janssen Biotech, Inc. Administered by Janssen Scientific Affairs, LLC
Merck
Pfizer, Inc.
Sanofi Genzyme
